Advocacy around research is important, especially because Down syndrome is the least funded genetic condition by the National Institutes of Health (NIH).
Aging with Down syndrome creates new health challenges. Families are helping each other by sharing what they learn.
In March 2018, 21 researchers published a study in the British Journal of Psychiatry called “Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study.”
Aims: To investigate the effect of cholinesterase inhibitors or memantine on survival and function in adults with Down syndrome and Alzheimer’s disease.
The researchers noted that there have been few studies conducted, and therefore little information is available on how to treat adults with Down syndrome and Alzheimer’s disease. They set out to test specific antidementia drugs on people with Down syndrome and Alzheimer’s disease. Continue reading Debate Over Study on Antidementia Drugs for Adults with Down Syndrome and Alzheimer’s Disease